In focus
Latest feed
A Decade of Dominance: How Cencora Stock Turned $1,000 into Nearly $6,700
Biohaven's Comeback: FDA Acceptance for Rare Disease Drug Ignites Hope and Shares
A New Chapter for Arbutus Biopharma: FDA Lifts Long-Standing Hold on Hepatitis B Drug
Fiserv's Mid-Year Pivot: A Deeper Look into Q2 2026 and What's Next